Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma
In Partnership With:
Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.
Yi Lin, MD, PhD, consultant, Division of Hematology, Department of Internal Medicine, consultant, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, assistant professor of medicine and oncology, Mayo Clinic, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.
Multiple BCMA-directed CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates are demonstrating significant efficacy for patients with multiple myeloma. However, the field is developing non-BCMA–targeted options as well, Lin explains.
Early data with non-BCMA–targeting approaches are showing high rates of early responses in patients, says Lin. With the rapid growth of immunotherapy in multiple myeloma, data will likely emerge in the coming years showing that non-BCMA–directed therapies are good options for patients, concludes Lin.
